Analysis Note

Low-end CV% Range: 5 - 12%|Low-end CV% Average: 9%

Application

Research CategoryMetabolism

Research Sub CategoryMetabolic Disorders

The sensitivity of Single Molecule Counting (SMC^®) technology gives the Total GLP-1 Immunoassay Kit unparalleled performance in the quantification of total GLP-1 in human EDTA plasma.

Used to detect/quantify:GLP-1 (Total)

Components

Total GLP-1 Coated Beads Vial 1Total GLP-1 Coated Beads Vial 2Total GLP-1 Standard DiluentGLP-1 Assay BufferTotal GLP-1 StandardTotal GLP-1 Detection AntibodySMC^®Total GLP-1 Immunoassay Kit Instructions10X Wash BufferElution Buffer BBuffer D

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial

General description

The SMC^® Total GLP-1 Immunoassay Kit contains all reagents required to perform the assay. This assay takes advantage of a standard immunoassay workflow configured in a standard plate format. Assay protocols are similar to existing sandwich ELISA methods with two key differences: 1) Elution buffer disrupts the sandwich, separating the labeled detection antibody for quantification. 2) The SMC^® immunoassay system detects analytes using Single Molecule Counting (SMC^®) technology.

Glucagon-Like Peptide-1 (GLP-1) is a member of the incretin family of hormones, which are released by the gut into the bloodstream in response to food. Post-translational cleavage of the peptide produces active GLP-1, which is then rapidly degraded by protease dipeptidyl peptidase-4 (DPP-4). When blood glucose level is high, active GLP-1 enhances insulin secretion and also suppresses the release of glucagon. In addition, GLP-1 stimulates the brain to trigger feelings of satiety and regulates the rate of gastric emptying. Compared to healthy controls, some patients with type-2 diabetes show a modest decrease in GLP-1 release. Therapeutic GLP-1 analogs such as exenatide, or DPP inhibitors like sitagliptin, are promising strategies for treating type-2 diabetes.

Legal Information

SMC is a registered trademark of Singulex